Chemotherapy for Progressive Low- Grade Gliomas in Children Older than Ten Years: The Dana-Farber Experience
|
|
- Anastasia Ball
- 5 years ago
- Views:
Transcription
1 See discussions, stats, and author profiles for this publication at: Chemotherapy for Progressive Low- Grade Gliomas in Children Older than Ten Years: The Dana-Farber Experience Article in Pediatric Hematology and Oncology October 2003 Impact Factor: 1.1 DOI: / Source: PubMed CITATIONS 13 READS authors, including: Liliana C Goumnerova Harvard Medical School 135 PUBLICATIONS 5,416 CITATIONS SEE PROFILE Available from: Liliana C Goumnerova Retrieved on: 10 May 2016
2 Pediatric Hematology and Oncology, 20: , 2003 Copyright C Taylor & Francis Inc. ISSN: print / online DOI: / CHEMOTHERAPY FOR PROGRESSIVE LOW-GRADE GLIOMAS IN CHILDREN OLDER THAN TEN YEARS: The Dana-Farber Experience John A. Heath and Christopher D. Turner Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children s Hospital, Boston, Massachusetts, USA Tina Young Poussaint Department of Radiology, Dana-Farber Cancer Institute and Children s Hospital, Boston, Massachusetts, USA R. Michael Scott and Liliana Goumnerova Department of Neurosurgery, Dana-Farber Cancer Institute and Children s Hospital, Boston, Massachusetts, USA Mark W. Kieran Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children s Hospital, Boston, Massachusetts, USA The purpose of this retrospective study was to examine the clinical and radiographic response rates to and toxicity of chemotherapy for low-grade gliomas in children older than 10 years of age. Between June 1999 and January 2001, seven consecutive children between the ages of 10 and 18 were treated with vincristine and carboplatin ± thioguanine, procarbazine, CCNU [lomustine], and vincristine (TPCV) for progressive low-grade gliomas. All 7 children completed a 10-week induction course of vincristine and carboplatin; 3 were switched to TPCV during the maintenance phase of therapy after developing an allergic reaction to carboplatin. Overall, 4 patients had a radiographic response to treatment with chemotherapy (3 partial responses and 1 minor response: objective response rate of 57%), and 2 more showed stable disease. One patient progressed while on treatment and 1 patient progressed off treatment, and after 31 months had elapsed. The resulting progression-free survival at the time of this report was 71%. The median duration of follow-up was 32 months (range months). Hematologic toxicity was common, but did not result in cessation of therapy. No other significant treatment-related toxicities were observed. The results suggest that the clinical response/disease stabilization rate in children older than 10 years of age does not differ markedly from that observed in younger children. A prospective clinical trial of chemotherapy for progressive low-grade gliomas in children older than 10 years is therefore warranted. Keywords. astrocytoma, chemotherapy, children, low-grade glioma Low-grade gliomas are the most common brain tumor of childhood, with about a third occurring in children older than 10 years of age [1, 2]. Complete surgical resection may be curative but for many of these tumors, particularly those involving midline structures, such as the thalamus, hypothalamus, and optic chiasm, this is not possible. While radiation may be a useful therapeutic tool in the treatment of these incompletely resected low-grade gliomas [3], Received 9 December 2002; accepted 25 May Address correspondence to Dr. John A. Heath, MD, PhD, Department of Clinical Haematology and Oncology, Royal Children s Hospital, Flemington Road Parkville, Victoria 3052 Australia. john.heath@rch.org.au 497
3 498 J. A. Heath et al. the potential for long-term side effects, such as intellectual deficits, impaired endocrine function, vascular changes, and second malignancies, has led to a desire to delay or avoid radiation in children [4, 5]. The role of chemotherapy as first-line therapy for unresectable, progressive low-grade gliomas (particularly younger children) has therefore been increasing. Numerous single and combination chemotherapeutic agents have been used for this purpose. These include vincristine/actinomycin D, vincristine/etoposide, vincristine/cisplatin, cyclophosphamide, tamoxifen/carboplatin, and carboplatin alone [6 12]. Many of the reported studies have upper age limits of less than 18 years, however. More recently, the combinations of vincristine/carboplatin [11] and thioguanine, procarbazine, CCNU [lomustine], and vincristine (TPCV) [13] have found favor for use in young children with recurrent or progressive low-grade gliomas. In a recent series of 78 patients with newly diagnosed, progressive low-grade gliomas treated with vincristine/carboplatin, an overall progression-free survival of 68 ± 7% at 3 years was achieved [11]. In addition, children less than 18 years with newly diagnosed or progressive low-grade gliomas treated with TPCV and dibromodulcitol had a 36% objective response rate, with a further 59% showing stable disease [13]. However, current trials examining the role of chemotherapy for progressive low-grade gliomas are restricted to children less than 10 years old [14]. This cutoff is somewhat arbitrary, since there is no evidence that the biologic behavior of tumors in older children is different from those in younger children. In addition, while the effects of radiation are most severe in younger children, it is recognized that even focal radiation in adults can be associated with neurocognitive deficits and intellectual decline over time [15]. The risks of endocrine deficits, vascular change, and second malignancy also persist for older children and adults. This retrospective, single-institution study therefore examined the clinical and radiographic response of low-grade gliomas in children older than 10 years to chemotherapy. PATIENTS AND METHODS Patient Characteristics The study was a retrospective review of children older than 10 years treated with chemotherapy for progressive low-grade gliomas between June 1999 and January 2001 at Dana-Farber Cancer Institute and Children s Hospital, Boston, MA. Patients had histologically confirmed low-grade astrocytomas (pilocytic or fibrillary) or other low-grade gliomas (WHO grade I or II), and documented progression of tumor on serial magnetic resonance imaging following the initial surgical excision. Patients with an incomplete excision, and a necessity to begin treatment because of an unacceptable risk of neurologic impairment with progression, were also included. In addition, children with
4 Chemotherapy for Low-Grade Gliomas in Children over 10 Years 499 neurofibromatosis type 1 (NF1) who had optic pathway tumors (presumed to be low-grade gliomas) with definitive radiographic evidence of progression were eligible without pathologic diagnosis. Apart from surgery, no child had received any previous therapy. Before beginning chemotherapy, all children had a complete history, physical and neurological examination. A baseline MRI for all and an ophthalmology examination for those with optic pathway tumors were also performed. To monitor for toxicity, a complete blood count, measurement of serum electrolytes, creatinine, and liver function tests, an assessment of glomerular filtration rate ( 99 Tm nuclear medicine scan), and an audiology evaluation were also undertaken. Treatment Regimen All patients initially received a 10-week induction course consisting of 8 doses of intravenous carboplatin (175 mg/m 2 ) and 10 doses of intravenous vincristine (1.5 mg/m 2, maximum 2 mg weekly) (Table 1). For patients with an objective response to treatment or for those with stable disease, maintenance therapy was administered for up to 8 cycles (Table 1). All children received ondansetron as prophylaxis against emesis. The carboplatin was administered in the outpatient department as a 30-min infusion with 1 h of prehydration and 1hofposthydration. All patients received trimethoprim/ sulfamethoxazole as Pneumocystis carinii prophylaxis. Toxicities were graded using the National Cancer Institute Common Toxicity Criteria. The complete blood count was monitored approximately weekly throughout the treatment period. Chemotherapy was deferred until the absolute neutrophil count (ANC) was > /L and the total platelet count was >100, /L. If the patient did not meet these hematologic criteria, therapy was delayed for 1 week. If grade 3 or 4 hematological, renal, or hepatic toxicity was documented, the dose of carboplatin was reduced by 25% for subsequent cycles. Vincristine was held for symptoms of grade 3 or 4 peripheral neuropathy, TABLE 1 Treatment (Vincristine and Carboplatin) During Induction and Maintenance Week Induction Vincristine a Carboplatin b Maintenance (begins 2 weeks later); repeat 8 Vincristine a Carboplatin b Note. +, administered;, not administered. a IV push 1.5 mg/m 2 (maximum 2 mg). b 175 mg/m 2 IV infusion.
5 500 J. A. Heath et al. TABLE 2 Treatment with TPCV(6-Thioguanine, Procarbazine, CCNU, and Vincristine) Chemotherapy Week Thioguanine a + Procarbazine b + CCNU c + Vincristine d + + Note. +, administered;, not administered. a Oral 30 mg/m 2 6-hourly for 12 doses. b Oral 50 mg/m 2 6-hourly for 4 doses. c Oral 110 mg/m 2. d IV push 1.5 mg/m 2 (maximum 2 mg). and only resumed at 66% dosage after symptoms improved to less than grade 2. Any patient who experienced an allergic reaction to carboplatin after receiving antihistamine and cortocosteroid premedication was switched to an alternative chemotherapy regimen of oral thioguanine, oral procarbazine, oral CCNU, and intravenous vincristine (TPCV) (Table 2). The initial and all subsequent cycles commenced after the ANC was > /L and platelets >100, /L. In cases of grade 3 or 4 hematological, renal, or liver toxicity, the doses of TPCV medications were reduced by 25% for subsequent cycles. Patients received up to 7 cycles of TPCV, depending on the total length of treatment and degree of myelosupression. Treatment was stopped if clinical or radiographic evidence of disease progression was documented. All patients and/or their responsible guardians provided written, informed consent for the treatment and all patients provided written assent to the treatment. Evaluation of Response All children had a complete physical and neurological examination prior to each course of chemotherapy. In addition, visual field testing was conducted every 3 months if clinically appropriate. An MRI scan of the tumor was undertaken every 3 months. Radiological response criteria were defined as follows: complete response (CR), the complete disappearance of tumor on imaging studies; partial response (PR), a reduction of 50% or more in tumor size, measured with maximum perpendicular diameters; minor response (MR), a reduction of at least 25% but less than 50% in tumor size; stable disease (SD), no change or a increase/decrease of less than 25% in tumor size; and progressive disease, any increase in tumor size greater than 25%. All radiographic studies were reviewed by one of the authors (TYP). Monitoring for toxicity included weekly complete blood counts and liver and renal
6 Chemotherapy for Low-Grade Gliomas in Children over 10 Years 501 function tests. In addition, repeat glomerular filtration rates and audiology were conducted every 3 months during treatment and initial follow-up. Statistical Analysis The primary objective of this review was to estimate the objective response rate (total number of CR, PR, and MR over total patients) of low-grade gliomas in children older than 10 years treated with chemotherapy. The secondary objective was to estimate the progression-free survival, measured from the date each patient was first administered chemotherapy to the date of excessive toxicity, progressive disease, death, or loss to follow-up. RESULTS From June 1999 to January 2001, seven consecutive children (5 boys, 2 girls) were treated with chemotherapy for progressive low-grade gliomas (Table 3). The median age at starting treatment was 14 years, 5 months (range 12 years, 9 months to 16 years, 3 months). At the time of this report, the median follow-up after initiation of chemotherapy was 32 months (range months). Response No child had a complete response to chemotherapy. Three patients had a partial response and 1 patient a minor response to chemotherapy, giving an overall objective response rate of 57%. Two patients showed this response after the completion of their induction therapy, while the other 2 showed continued shrinkage throughout the maintenance phase of therapy. A further 2 patients exhibited stable disease, resulting in an overall failure to progress rate of 86%. One patient (ganglioglioma) showed asymptomatic radiographic evidence of progression 3 months after commencing chemotherapy. He was subsequently taken off chemotherapy and treated with 5580 cgy TABLE 3 Clinical Characteristics of 7 Older Children Treated with Chemotherapy for Low-Grade Gliomas Age at Previous Time to Patient Sex treatment NF1 Diagnosis Site treatment progress 1 Female 12 y, 9 m Yes Glioma R optic nerve Nil 6 y, 9 m 2 Male 14 y, 9 m No Pilocytic L optic nerve Biopsy 1 y, 10 m 3 Male 14 y, 6 m No Ganglioglioma L temporal STR 2, 3y,8m 4 Female 12 y, 9 m No Pilocytic Brainstem STR 0 y, 3 m 5 Male 14 y, 5 m No Pilocytic Hypothalamic STR 4 y, 10 m 6 Male 16 y, 3 m No Pilocytic Hypothalamic Biopsy 0 a 7 Male 13 y, 2 m Yes Glioma Optic tract Nil 10 y, 2 m Note. y, years; m, months; STR, sub-total resection. a Patient was treated at the time of initial diagnosis.
7 502 J. A. Heath et al. TABLE 4 Clinical and Radiographic Evaluation of the Response to Chemotherapy in 7 Children Older Than 10 Years Treated with Chemotherapy for Low-Grade Gliomas Patient Cycles VC (I a ) TPCV (M b ) Before therapy (cm) After induction (cm) Therapy completed (cm) Response Follow-up c (months) PR PR PD SD MR SD PR 27 Note. Patient 2 suffered an asymptomatic radiographic progression at 31 months and 5s rece5v5ng f6ca3 5rrad5at56n. a Weeks of induction treatment. b Maintenance cycles. c Measured from commencement of therapy. focal irradiation with good effect. No patient with an optic tract tumor showed a deterioration on visual field testing and no child showed clinical neurologic deterioration while on chemotherapy. Five of 6 children with either an objective response to treatment or stable disease remain unchanged or improved at the time of submission of this report. One child (who initially had a partial response) showed asymptomatic radiologic progression 31 months after the commencement of chemotherapy and is currently being treated with 5580 cgy focal irradiation (Table 4). Toxicity In addition to the 10-week vincristine/carboplatin induction chemotherapy, a total of 29 vincristine/carboplatin maintenance cycles and 18 TPCV cycles were given. There were a total of 8 episodes of grade 3/4 hematologic toxicity in those patients receiving vincristine/carboplatin (Table 5). Three children had an allergic reaction to carboplatin (hives and/or bronchospasm) that was not responsive to premedication. This necessitated a switch to TPCV chemotherapy. Patients treated with TPCV after commencing on vincrisine/carboplatin suffered a total of 10 episodes of grade 3/4 TABLE 5 Worst Toxicity in 7 Children Older Than 10 Years Receiving Chemotherapy for Progressive Low-Grade Gliomas Number (/7) Number (/3) Hematological toxicity vincristine/carboplatin TPCV Grade 3 or 4 neutropenia 3 2 Grade 3 or 4 thrombocytopenia 0 2 Grade 3 or 4 anemia 1 0 Note. Carboplatin allergy = 3, vincristine neuropathy = 4.
8 Chemotherapy for Low-Grade Gliomas in Children over 10 Years 503 hematologic toxicity. Additionally, there were 5 episodes of vincristine-related neuropathy severe enough to require dose reduction. No patient experienced significant hearing loss or any impairment of renal or liver function throughout the treatment or in the follow-up period. No child has developed a second malignancy. DISCUSSION Based on this small series, children older than 10 years of age with progressive low-grade gliomas appear to have similar clinical response/disease stabilization rates to chemotherapy when compared to those reported in younger children. Of the 7 children treated in this retrospective study, 4 had an objective radiographic response to the chemotherapy and 2 more exhibited stable disease. Given previous experience showing there is no difference in disease control in patients who had a complete or partial response to chemotherapy compared to those who had a minor response or stable disease [6], our results are encouraging for the longer term. Previously, children less than 5 years treated with vincristine/carboplatin have been reported to have 3-year progression-free survival rates of 74 ± 7%, compared to a rate of 39 ± 21% for older children [6]. The reason for the poorer response in older children is not clear, and to date has not been corroborated in any subsequent study. In fact, older children with optic chiasm gliomas treated with carboplatin alone (560 mg/m 2 monthly) have been reported to have an 83% progression-free survival at 39 months [16]. While not all of our cohort have been followed for this length of time, the 2-year progression-free survival rate of 86% (n = 7) is not inconsistent with a positive long-term outcome. Only 1 of our 6 patients who initially showed a partial response has progressed 31 months after the commencement of chemotherapy. To date, the 2 patients with NF1 have avoided exposure to radiation therapy entirely. While the number is small, it may be an important finding, given the recognized susceptibility for malignant transformation in these patients [17]. Even if the relapse rate for the remaining patients were to increase with time, the delay in exposure to radiation therapy may still be a worthwhile endpoint. Clearly, more detailed studies of the age-related effects of radiation therapy will be needed to clarify this. It is of interest that the only tumor that progressed in spite of chemotherapy was the single case of ganglioglioma within the cohort. Whether this reflects an inherent biologic difference in the tumor remains to be seen, and is the subject of a separate ongoing evaluation. The 2 chemotherapy regimens used appeared to be well tolerated with only moderate and reversible toxicities observed. The high incidence of allergic reactions to carboplatin makes its use somewhat problematic, however. Our experience is very similar to that observed in younger children, where weekly exposure to intravenous carboplatin has been associated with allergic
9 504 J. A. Heath et al. reaction rates as high as 50% [18]. Fortunately, all 3 patients who switched over to TPCV were able to complete 18 months of chemotherapy and have not progressed to date. Clearly, the length of follow-up in this study is short; older children have been followed for between 25 and 42 months. This period of time may well be critical for the population under study, however, given that a delay in or omission of radiation through the period of puberty may well improve growth. Further follow-up will be required to determine whether treatment with chemotherapy has a longer term effect on tumor growth and if indeed a significant reduction in long-term morbidity can be achieved. We conclude that further prospective clinical trials examining the role of chemotherapy in the treatment of older children with progressive low-grade gliomas are warranted. REFERENCES 1. Giles FH, Consortium CBT. A study of childhood brain tumors based on surgical biopsies from ten North American institutions: sample description. Childhood Brain Tumor Consortium. J Neurooncol. 1988;6: Farwell JR, Dohrmann GJ, Flannery JT. Central nervous system tumors in children. Cancer. 1977;40: Fisher BJ, Bauman GS, Leighton CE, Stitt L, Cairncross JG, Macdonald DR. Low-grade gliomas in children: tumor volume response to radiation. J Neurosurg. 1998;88: Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D Angio G. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol. 1987;15: Constine LS, Woolf PD, Cann D, et al. Hypothalamic pituitary dysfunction after radiation for brain tumors. N Engl J Med. 1993;328: Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol. 1988;23: Pons MA, Finlay JL, Walker RW, Puccetti D, Packer RJ, McElwain M. Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. J Neurooncol. 1992;14: Kato T, Sawamura Y, Tada M, Ikeda J, Ishii N, Abe H. Cisplatin/vincristine chemotherapy for hypothalamic/visual pathway astrocytoms in young children. J Neurooncol. 1998;37: Kadota RP, Kun LE, Langston JW, et al. Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1999;21: Walter AW, Gajjar A, Reardon DA, et al. Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children s Research Hospital. J Pediatr Hematol Oncol. 2000;22: Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86: Mahoney DH Jr, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-oncology. 2000;2: Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32: Ater JC, and Children s Cancer Group. Protocol A9952: chemotherapy for progressive low-grade astrocytoma in children less than ten years old. A Phase III Intergroup CCG/POG Study. 1997: al-mefty O, Kersh JE, Routh A, Smith RR. The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg. 1990;73: Aquino VM, Fort DW, Kamen BA. Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neurooncol. 1999;41: Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5: Yu DY, Dahl GV, Shames RS, Fisher PG. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol. 2001;23:
10
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas
Neurosurg Focus 4 (4):Article 3, 1998 Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas Albert Moghrabi, M.D., Henry S. Friedman, M.D., David M. Ashley, M.B.B.S., Ph.D., Krystal S.
More informationMee Jeong Lee Æ Young Shin Ra Æ Jun Bum Park Æ Hyun Woo Goo Æ Seung Do Ahn Æ Shin Kwang Khang Æ Joon Sup Song Æ Yoon Jung Kim Æ Thad T.
J Neurooncol (2006) 80:277 284 DOI 10.1007/s11060-006-9185-2 CLINICAL PATIENT STUDIES Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide,
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationPrior to 1993, the only data available in the medical
Neuro-Oncology Prospective clinical trials of intracranial low-grade glioma in adults and children Edward G. Shaw 1 and Jeffrey H. Wisoff Department of Radiation Oncology, Wake Forest University School
More informationRadiotherapy in the management of optic pathway gliomas
Turkish Journal of Cancer Vol.30/ No.1/2000 Radiotherapy in the management of optic pathway gliomas FARUK ZORLU, FERAH YILDIZ, MURAT GÜRKAYNAK, FADIL AKYOL, İ. LALE ATAHAN Department of Radiation Oncology,
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationLOW-GRADE gliomas include astrocytomas, oligodendrogliomas,
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma By Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon,
More informationProtocol Abstract and Schema
Protocol Abstract and Schema Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma. Description and Rationale: Craniopharyngiomas account
More informationTheodore S. Johnson, MD, PhD
Front-line Therapy of DIPG Using IDO Pathway Inhibitor Indoximod in Combination with Radiation and Chemotherapy American Association of Cancer Research (AACR) 2018 Theodore S. Johnson, MD, PhD Georgia
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationPediatric low-grade glioma
J Radiat Oncol (2013) 2:129 133 DOI 10.1007/s13566-012-0078-z REVIEW Pediatric low-grade glioma Anita Mahajan Received: 21 October 2012 / Accepted: 6 November 2012 / Published online: 19 November 2012
More informationBC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy
BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent Adjuvant Temozolomide Radiation Therapy Protocol Code Tumour Group Contact Physician CNELTZRT Neuro-Oncology
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationChemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
More informationCNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician
BC Cancer Protocol Summary for Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation Protocol Code Tumour Group Contact
More informationOutstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014
Outstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014 Answers provided as a courtesy by Dana Farber Cancer Institute experts: Dr. Mark Kieran Dr. Peter Manley
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationProtocol Abstract and Schema
Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy
More informationA clinical study of Thalamic gliomas and its treatment modalities
Bhagwati Salgotra and Kunal Kishore / International Journal of Biomedical and Advance Research 2015; 6(10): 725-729. 725 International Journal of Biomedical and Advance Research ISSN: 2229-3809 (Online);
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationTemozolomide in the treatment of recurrent malignant glioma in Chinese patients!"#$%&'()*+,-./0,1234
Key words: Astrocytoma; Brain neoplasms; Disease-free survival; Glioblastoma; Neoplasm recurrence!!"!"!"#$ DTM Chan WS Poon YL Chan HK Ng Hong Kong Med J 2005;11:452-6 The Chinese University of Hong Kong,
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationBC Cancer Protocol Summary for Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
BC Cancer Protocol Summary for Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine Protocol Code Tumour Group Contact Physician CNBEV
More informationLong term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era
334 Pediatrics, Gustave Roussy Institute, 39 rue Camille Desmoulins, 945 Villejuif, Cedex, France C Cappelli J Grill M Raquin O Hartmann C Kalifa Pathology, Gustave Roussy Institute M-J Terrier-Lacombe
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationOutcome and Prognostic Features in Pediatric Gliomas
Outcome and Prognostic Features in Pediatric Gliomas A Review of 6212 Cases From the Surveillance, Epidemiology, and End Results Database Ibrahim Qaddoumi, MD, MS 1 ; Iyad Sultan, MD 2 ; and Amar Gajjar,
More informationA Boy with Optic Glioma
Clin Pediatr Endocrinol 1994;3(Suppl 4): 169-173 Copyright(C)1994 by The Japanese Society for Pediatric Endocrinology Taisuke Okada, Sumitaka Dohno, Yousei Shimasaki, Takashi Tomoda, Makiko Koga, Kumiko
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationStandard care plan for Carboplatin and Etoposide Chemotherapy References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Currency: Carboplatin/Etoposide Chemotherapy Clinical Guideline Standard Care Plan 2 Years Review date: Author(s): Standard care
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationSmall and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
More informationNON MALIGNANT BRAIN TUMOURS Facilitator. Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol
NON MALIGNANT BRAIN TUMOURS Facilitator Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol Neurosurgery What will be covered? Meningioma Vestibular schwannoma (acoustic neuroma)
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationGERM CELL TUMOUR PI GC-1
GERM CELL TUMOUR PI GC-1 NCCN Pacific Island Working Group Clinical Members Scott Macfarlane Peter Bradbeer Jane Skeen Rob Corbett Radhika Sandilya Page 1 2 TREATMENT OUTLINE 6* cycles of identical treatment
More informationTemozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience
Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationA Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)
A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) Morten Mau-Sorensen 1, Scott Plotkin 2, Patrick Wen 3, Andrew
More informationCisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:
Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Protocol INDICATION ICD10 Code Small cell lung cancer (SCLC) limited disease C34 00279a ELIGIBILTY: Indications as above ECOG 0-2
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 17 November 2010 MEPACT 4 mg, powder for suspension for infusion B/1 (CIP code: 398331 6) Applicant : IDM PHARMA S.A.S
More informationProcarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE:
Procarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Adjuvant treatment of Grade II glioma administered after C71 00379a radiotherapy Palliative treatment
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
Outpatient Anti Cancer Treatment Handbook LCV Lomustine, Cisplatin, Vincristine Packer Regimen Repeated every 6 weeks for a maximum of 6 cycles Approved for use in: Medulloblastoma adjuvant therapy Dosage:
More informationFludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study
Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes. ***See protocol for further details*** Available for Routine Use in
More informationTRANSPARENCY COMMITTE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTE OPINION 19 December 2007 ATRIANCE 5 mg/ml, Solution for Infusion Pack of 6 vials (571 348-9) Applicant: GlaxoSmithKline nelarabine
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician BRAJDCARBT Breast Dr. Susan Ellard
More informationEpidemiology, Management and Treatment Outcome of Medulloblastoma in Singapore
314 Original Article Epidemiology, Management and Treatment Outcome of Medulloblastoma in Singapore Mei-Yoke Chan, 1 MBBS, MMed (Paeds), MRCP (UK), Wan-Yee Teo, 2 MBBS, Wan-Tew Seow, 3 MBBS, FRACS (Neurosurg),
More informationBRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationSignificant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions
Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Susannah E. Koontz, PharmD, BCOP Clinical Pharmacy & Education Consultant Pediatric Hematology/Oncology and
More informationOptic Pathway Gliomas, Germinomas, Spinal Cord Tumours. Colin Kennedy March 2015
Optic Pathway Gliomas, Germinomas, Spinal Cord Tumours Colin Kennedy March 2015 Glioma of the optic chiasm. T1-weighted MRI with gadolinium enhancement, showing intense irregular uptake of contrast. The
More information1. FBE,UEC, LFT 2. USS of eyes confirm intraocular origin, possible calcifications. 3. CT(if available) of eyes and head
Retinoblastoma PNG V2 Treatment Guidelines for PNG Retinoblastoma 01V1 Current aim of treatment is to preserve life, vision preservation is secondary at this time. Retinoblastoma remains intra ocular and
More informationSUPPLEMENTARY INFORMATION In format provided by Sebti et al. (NOVEMBER 2011)
Supplementary Information S4 Clinical trials with farnesyltransferase inhibitors Drug(s) Disease Phase Patients Median Age Tipifarnib CR Clinical response PR HI SD PD MD FT or Prenylation Response rate
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationProtocol Abstract and Schema
Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
More informationCOG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Page 1 of 6 COG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) FAST FACTS Eligibility Reviewed and Verified By
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationAntiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild and Moderately Emetogenic Chemotherapy
218 Journal of Pain and Symptom Management Vol. 18 No. 3 September 1999 Original Article Antiemetic Prophylaxis with Ondansetron and Methylprednisolone vs Metoclopramide and Methylprednisolone in Mild
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationOriginal Study. 40 Clinical Lung Cancer January 2013
Original Study Prophylactic Cranial Irradiation for Patients With Limited-Stage Small-Cell Lung Cancer With Response to Chemoradiation Patricia Tai, 1 Avi Assouline, 2 Kurian Joseph, 3 Larry Stitt, 4 Edward
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-GCVP.DOC CONTROLLED DOC NO: HCCPG B12 CSIS Regimen Name: R-GCVP. R-GCVP Regimen
R-GCVP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication CD 20 positive
More informationScottish Medicines Consortium
Scottish Medicines Consortium clofarabine, 1mg/ml concentrate for solution for infusion (Evoltra ) (No. 327/06) Bioenvision Limited 8 December 2006 The Scottish Medicines Consortium (SMC) has completed
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationBC Cancer Protocol Summary for the Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality
BC Cancer Protocol Summary for the Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality Protocol Code Tumour Group Contact Physician MYBORMTN
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationResponse to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas
ONCOLOGY LETTERS 4: 455-460, 2012 Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas MICHAL SPYCH 1,2, LESZEK GOTTWALD 3, EMILIA JESIEŃ LEWANDOWICZ 1,2, SŁAWOMIR
More informationNeuroblastoma. Elizabeth Roberts. Data Coordinator CIBMTR Data Managers Mentor. Tandem Meeting February 18
Neuroblastoma Elizabeth Roberts Data Coordinator CIBMTR Data Managers Mentor Tandem Meeting February 18 Objectives Know what neuroblastoma is, how it is diagnosed, and how it is treated Complete form 2026:
More informationLong-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery
J Neurosurg 83:583 589, 1995 Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery LESLIE N. SUTTON, M.D., PATRICIA T. MOLLOY, M.D., HEIDI SERNYAK, B.A.,
More informationE 90 C followed by Weekly Paclitaxel
E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationGOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist:
BCCA Protocol Summary for Primary Treatment of Stage III less than or equal to 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More information